Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

AIMS: AZD9977 is the first mineralocorticoid receptor modulator in clinical development exerting similar organ protection as eplerenone with minimal urinary electrolyte effects in preclinical studies. The aim was to perform the initial clinical assessment of AZD9977. METHODS: A first‐in‐human trial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Erlandsson, Fredrik, Albayaty, Muna, Chialda, Ligia, Ericsson, Hans, Amilon, Carl, Nelander, Karin, Jansson‐Löfmark, Rasmus, Wernevik, Linda, Kjaer, Magnus, Bamberg, Krister, Hartleib‐Geschwindner, Judith
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6005625/
https://ncbi.nlm.nih.gov/pubmed/29468715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13562
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados